연구성과로 돌아가기

2024 연구성과별 연구자 정보 (446 / 2344)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
Comparison of Recombinant Human Thyroid-Stimulating Hormone and Thyroid Hormone Withdrawal for ¹³¹I Therapy in Patients With Intermediate- to High-Risk Thyroid Cancer Seo, Youngduk Seo, Y 4 Chungnam Natl Univ, Sejong Hosp, Dept Nucl Med, Sejong, South Korea 0000-0002-9779-9060 Seo, Youngduk arieshamal@snu.ac.kr;bangjiin@gmail.com;mdbabyduck@gmail.com;arichong.md@gmail.com;cmhong@knu.ac.kr;dong-eun@ncc.re.kr;mychoi@neca.re.kr;swleenm@knu.ac.kr;mdosw@snu.ac.kr;
Comparison of Recombinant Human Thyroid-Stimulating Hormone and Thyroid Hormone Withdrawal for ¹³¹I Therapy in Patients With Intermediate- to High-Risk Thyroid Cancer Chong, Ari Chong, A 5 Chosun Univ Hosp, Dept Nucl Med, Gwangju, South Korea arieshamal@snu.ac.kr;bangjiin@gmail.com;mdbabyduck@gmail.com;arichong.md@gmail.com;cmhong@knu.ac.kr;dong-eun@ncc.re.kr;mychoi@neca.re.kr;swleenm@knu.ac.kr;mdosw@snu.ac.kr;
Comparison of Recombinant Human Thyroid-Stimulating Hormone and Thyroid Hormone Withdrawal for ¹³¹I Therapy in Patients With Intermediate- to High-Risk Thyroid Cancer Chong, Ari Chong, A 5 Coll Med, Gwangju, South Korea arieshamal@snu.ac.kr;bangjiin@gmail.com;mdbabyduck@gmail.com;arichong.md@gmail.com;cmhong@knu.ac.kr;dong-eun@ncc.re.kr;mychoi@neca.re.kr;swleenm@knu.ac.kr;mdosw@snu.ac.kr;
Comparison of Recombinant Human Thyroid-Stimulating Hormone and Thyroid Hormone Withdrawal for ¹³¹I Therapy in Patients With Intermediate- to High-Risk Thyroid Cancer Hong, Chae Moon Hong, CM 6 Kyungpook Natl Univ, Sch Med, Dept Nucl Med, Daegu, South Korea 0000-0002-5519-6982 Hong, Chae Moon arieshamal@snu.ac.kr;bangjiin@gmail.com;mdbabyduck@gmail.com;arichong.md@gmail.com;cmhong@knu.ac.kr;dong-eun@ncc.re.kr;mychoi@neca.re.kr;swleenm@knu.ac.kr;mdosw@snu.ac.kr;
Comparison of Recombinant Human Thyroid-Stimulating Hormone and Thyroid Hormone Withdrawal for ¹³¹I Therapy in Patients With Intermediate- to High-Risk Thyroid Cancer Lee, Dong-Eun Lee, DE 7 Natl Canc Ctr, Biostat Collaborat Team, Goyang, South Korea arieshamal@snu.ac.kr;bangjiin@gmail.com;mdbabyduck@gmail.com;arichong.md@gmail.com;cmhong@knu.ac.kr;dong-eun@ncc.re.kr;mychoi@neca.re.kr;swleenm@knu.ac.kr;mdosw@snu.ac.kr;
Comparison of Recombinant Human Thyroid-Stimulating Hormone and Thyroid Hormone Withdrawal for ¹³¹I Therapy in Patients With Intermediate- to High-Risk Thyroid Cancer Choi, Miyoung Choi, M 8 Div Healthcare Technol Assessment Res, Natl Evidence Based Healthcare Collaborating Agcy, Seoul, South Korea arieshamal@snu.ac.kr;bangjiin@gmail.com;mdbabyduck@gmail.com;arichong.md@gmail.com;cmhong@knu.ac.kr;dong-eun@ncc.re.kr;mychoi@neca.re.kr;swleenm@knu.ac.kr;mdosw@snu.ac.kr;
Comparison of Recombinant Human Thyroid-Stimulating Hormone and Thyroid Hormone Withdrawal for ¹³¹I Therapy in Patients With Intermediate- to High-Risk Thyroid Cancer Lee, Sang-Woo Lee, SW 9 Kyungpook Natl Univ, Sch Med, Dept Nucl Med, Daegu, South Korea KUD-1906-2024 lee, sangwoo arieshamal@snu.ac.kr;bangjiin@gmail.com;mdbabyduck@gmail.com;arichong.md@gmail.com;cmhong@knu.ac.kr;dong-eun@ncc.re.kr;mychoi@neca.re.kr;swleenm@knu.ac.kr;mdosw@snu.ac.kr;
Comparison of Recombinant Human Thyroid-Stimulating Hormone and Thyroid Hormone Withdrawal for ¹³¹I Therapy in Patients With Intermediate- to High-Risk Thyroid Cancer Lee, Sang-Woo Lee, SW 9 Chilgok Hosp, Daegu, South Korea KUD-1906-2024 lee, sangwoo arieshamal@snu.ac.kr;bangjiin@gmail.com;mdbabyduck@gmail.com;arichong.md@gmail.com;cmhong@knu.ac.kr;dong-eun@ncc.re.kr;mychoi@neca.re.kr;swleenm@knu.ac.kr;mdosw@snu.ac.kr;
Comparison of Recombinant Human Thyroid-Stimulating Hormone and Thyroid Hormone Withdrawal for ¹³¹I Therapy in Patients With Intermediate- to High-Risk Thyroid Cancer Oh, So Won Oh, SW 10 교신저자 Seoul Natl Univ, Boramae Med Ctr, Dept Nucl Med, 20 Boramae Ro 5 Gil, Seoul 07061, South Korea arieshamal@snu.ac.kr;bangjiin@gmail.com;mdbabyduck@gmail.com;arichong.md@gmail.com;cmhong@knu.ac.kr;dong-eun@ncc.re.kr;mychoi@neca.re.kr;swleenm@knu.ac.kr;mdosw@snu.ac.kr;
Comparison of Short-Term Outcomes and Safety Profiles between Androgen Deprivation Therapy plus Abiraterone/Prednisone and Androgen Deprivation Therapy plus Docetaxel in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer Park, Dong Jin Park, DJ 1 Dongguk Univ, Coll Med, Dept Urol, Gyeongju, South Korea 0000-0003-1667-2146 Park, Dong Jin skhwan.script@gmail.com;
Comparison of Short-Term Outcomes and Safety Profiles between Androgen Deprivation Therapy plus Abiraterone/Prednisone and Androgen Deprivation Therapy plus Docetaxel in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer Kwon, Tae Gyun Kwon, TG 2 Kyungpook Natl Univ, Sch Med, Dept Urol, Daegu, South Korea 0000-0002-4390-0952 KWON, TAE GYUN skhwan.script@gmail.com;
Comparison of Short-Term Outcomes and Safety Profiles between Androgen Deprivation Therapy plus Abiraterone/Prednisone and Androgen Deprivation Therapy plus Docetaxel in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer Park, Jae Young Park, JY 3 Korea Univ, Ansan Hosp, Dept Urol, Ansan, South Korea AFQ-0813-2022 Park, Jae Young 0000-0002-6664-6846 Park, Jae young skhwan.script@gmail.com;
Comparison of Short-Term Outcomes and Safety Profiles between Androgen Deprivation Therapy plus Abiraterone/Prednisone and Androgen Deprivation Therapy plus Docetaxel in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer Joung, Jae Young Joung, JY 4 Natl Canc Ctr, Ctr Prostate Canc, Dept Urol, Goyang, South Korea skhwan.script@gmail.com;
Comparison of Short-Term Outcomes and Safety Profiles between Androgen Deprivation Therapy plus Abiraterone/Prednisone and Androgen Deprivation Therapy plus Docetaxel in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer Ha, Hong Koo Ha, HK 5 Pusan Natl Univ, Pusan Natl Univ Hosp, Sch Med, Dept Urol, Busan, South Korea W-1873-2019 Ha, Hong skhwan.script@gmail.com;
Comparison of Short-Term Outcomes and Safety Profiles between Androgen Deprivation Therapy plus Abiraterone/Prednisone and Androgen Deprivation Therapy plus Docetaxel in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer Jeon, Seong Soo Jeon, SS 6 Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Urol, Seoul, South Korea skhwan.script@gmail.com;
페이지 이동: